Oncopharmpod

Trastuzumab deruxtecan vs. trastuzumab trastuzumab

We look at two recent studies that illustrate a framework for how we identify risk factors and possible predictors of chemotherapy toxicity. Paclitaxel and skeletal muscle mass: https://doi.org/10.1111/bcp.15244 Sex differences of toxicity risk: https://doi.org/10.1200/jco.21.02377

Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.

The Landmarks of OncoPharm series returns to discuss the origins of "7 + 3" 7 + 3 > 5 + 2: https://doi.org/10.1182/blood.V58.6.1203.1203

We discuss the evolution of metastatic prostate cancer treatments leading up to last week's publication of ARASENS. Also, PROPEL and MAGNITUDE hint at an earlier role in therapy of PARP-inhibitors in prostate cancer. Maybe.

Foundations of OncoPharm: BCG and its fascinating history and role in non-muscle invasive bladder cancer. History of BCG: https://pubmed.ncbi.nlm.nih.gov/17997439/

This week we hype the seemingly negative impact of KIR2DS1/HLA-C2/C2 genotype on rituximab benefit in aggressive lymphomas. We also cover updates in breast cancer (pembrolizumab in TNBC; AIs in pre-menopausal women) and cervical cancer (cemiplimab). KIR & Rituximab: https://doi.org/10.1016/S2352-3026(21)00369-0 Keynote-522 Update w/ EFS analysis: https://www.nejm.org/doi/full/10.1056/NEJMoa2112651 Premenopausal Breast Cancer AIs vs. Tam Meta-Analysis: https://doi.org/10.1016/S1470-2045(21)00758-0 Cemiplimab in cervical cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2112187

We quickly cover some of the ASCO GI highlights from a couple weeks ago and delve deep into the role of ICIs in metastatic esophageal caner. Finally, does tebentafusp's approval tell us anything about the future intersection of immunotherapy and precision medicine?

Dr. Howard McLeod joins the pod to talk Precision Medicine and the role pharmacists can play using pharmacogenomics and tumor genomics in cancer care. https://www.drhowardmcleod.com

Topic covered include the latest updates to the seminal Hallmarks of Cancer work, adjuvant pembrolizumab for stage IIB/IIC melanoma, a prospective study of UGT1A1 testing, and Keynote-775. Hallmarks of Cancer: New Dimensions. https://cancerdiscovery.aacrjournals.org/content/12/1/31 UGT1A1 Genotype-guided dosing of irinotecan: https://doi.org/10.1016/j.ejca.2021.12.009 Keynote-775: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330

Foundations of OncoPharm: Carfilzomib (and a fair bit of bortezomib)

We're joined by Dr. Ryan McDade to hear about working as a Clinical Pharmacy Lead for Humana Specialty Pharmacy.

Happy Holidays!

Reviewing some big news from ASH21 concerning DLBCL that has us asking, "the more the change, the more R-CHOP remains the same?" Also, we talk CAR-T (ZUMA-7 & BELINDA), sotorasib, a possible way to predict poor response to ICI (HLA-A*03), and Evusheld as a possible way to protect those patients destined to a poor vaccine response from COVID.

The 2nd episode in our Career Paths series features Dr. Morgan Randolph. She gives great insight into her role as pediatric oncology pharmacist and the choice between a PGY2 in Pediatrics or Oncology for those considering that decision.

Lots of updates to discuss from dasatinib dosing to ICI/TKI sequencing in BRAF-mutated metastatic melanoma to adjuvant chemo in node (+) breast cancer to some FDA approval updates.

Discussing one of the more intriguing studies of the year looking at whether metastatic melanoma survival is effected by what time of day immunotherapy is administered. Link: https://doi.org/10.1016/S1470-2045(21)00546-5

What is a medical science liaison (MSL) and what do they do? Our 1st episode in a series highlighting different career options for oncology pharmacists featuring Dr. Christan Thomas.

Asciminib is now FDA approved and it's not just another TKI for CML

From IMPOWER 010 to NIFTY to CONFIRM to SOLO, there's lots to discuss on this episode. Adjuvant atezolizumab for select NSCLC patients now FDA approved. 5-year f/u of olaparib maintenance in mBRCA ovarian cancer smells funny: https://doi.org/10.1016/S1470-2045(21)00531-3 CONFIRM: https://doi.org/10.1016/S1470-2045(21)00471-X NIFTY: https://doi.org/10.1016/S1470-2045(21)00486-1 Palbociclib-PPI Interaction? https://doi.org/10.1016/j.esmoop.2021.100231